MetaVia Inc. is a clinical-stage biotechnology company focused on developing novel therapies for cardiometabolic diseases. The company’s current programs center on obesity and metabolic dysfunction-associated steatohepatitis (MASH), with an emphasis on drug candidates designed to address metabolic regulation, appetite control, and related disease pathways. MetaVia’s pipeline also includes research in type 2 diabetes and other cardiometabolic conditions, reflecting its broader focus on diseases linked to metabolic dysfunction. Based in Cambridge, Massachusetts, MetaVia operates in the biopharmaceutical sector, where its role is to advance early- and mid-stage drug development through clinical testing and therapeutic innovation.
Website545 Concord Avenue
Cambridge, MA, 02138
United States
Detailed price information for Amylyx Pharmaceuticals Inc (AMLX-Q) from The Globe and Mail including charting and trades.
By David Bautz, PhD NASDAQ: MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Dose Titration Complete in Phase 1 Part 3 Study of DA-1726 MetaVia, Inc. (NASDAQ: MTVA) is currently conducting Part 3 of the Phase 1 study of DA-1726, the company’s oxyntomodulin analog agonist that targets glucagon-like peptide-1 receptors (GLP1R) and glucagon receptors (GCGR), for the treatment of obesity. The
Detailed price information for Metavia Inc (MTVA-Q) from The Globe and Mail including charting and trades.
Investors talking about MTVA also mention
What share of all stock conversation is about MTVA?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% 0 | 0% +0 | 0% 0 |
Of the messages about MTVA that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | — | — | 62.94% -5.36 | ||
| Bearish | — | — | — | 37.06% +5.36 |
Of the messages about MTVA that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | — | 100% | 34.85% | ||
| Analysts | — | — | 0% | 25.82% | ||
| Controversies | — | — | 0% | 0% | ||
| Earnings | — | — | 0% | 0.2% | ||
| Macro | — | — | 0% | 21.94% | ||
| Technical Analysis | — | — | 0% | 17.19% |
Of the messages about MTVA, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | — | — | 0% | 10.13% | ||
| Newcomers | — | — | 100% | 89.87% |